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ABSTRACT 
 
There is a robust association between psychosis and cannabis use, but the mechanisms 
underlying this relation are poorly understood. Because both psychosis and cannabis use 
have been linked to cardiovascular problems, it is possible that cannabis use exacerbates 
an underlying vascular vulnerability in individuals prone to psychosis. To investigate 
microvascular differences in individuals with psychotic symptoms and cannabis use, the 
current study tested associations between psychotic-like experiences, cannabis use, and 
retinal vessel diameter in 101 young adults (mean age=19.37 years [SD=1.93]). Retinal 
venular diameter did not differ between participants with (M=218.08, SD=15.09) and 
without psychotic-like experiences (M=216.61, SD=16.18) (F(1, 97)=0.01, p=.93) or 
between cannabis users (M=218.41, SD=14.31) and non-users (M=216.95, SD=16.26) 
(F(1, 97)=0.37, p=.54). Likewise, mean retinal arteriolar diameter did not differ between 
participants with (M=157.07, SD=10.96) and without psychotic-like experiences 
(M=154.88, SD=9.03) (F(1, 97)=0.00, p=.97). However, cannabis users had statistically 
significantly wider retinal arterioles (M=159.10, SD=9.94) than did non-users 
(M=154.29, SD=10.20) (F(1, 97)=5.99, p=.016), and this effect was robust to control for 
covariates. There was no evidence of an interaction between psychotic-like experiences 
and cannabis use in predicting retinal vessel diameter. These results indicate that 
cannabis use is associated with microvascular differences in young adulthood. Given 
current trends toward legalization of recreational cannabis use, future research should 
explore these differences and their potential consequences for cardiovascular health.  
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Introduction 
There is a well-established link between cannabis use and psychosis, but the 
mechanisms underlying the relation remain unclear (Arseneault et al., 2002; Fergusson, 
Horwood, & Swain-Campbell, 2003; Henquet et al., 2005 Stefanis et al., 2004; van Os et 
al., 2002; Weiser, Knobler, Noy, & Kaplan, 2002; Zammit, Allebeck, Andreasson, 
Lundberg, & Lewis, 2002). Considerable evidence suggests that cannabis use may 
exacerbate an underlying vulnerability to psychosis (Caspi et al., 2005; Hall & 
Degenhardt, 2014; Malone, Hill, & Rubino, 2010; van Winkel & Kuepper, 2014). I 
hypothesize that one way cannabis use may trigger psychosis is by exacerbating 
underlying vascular risk. Accumulating evidence suggests that individuals with psychosis 
have an underlying vascular vulnerability (Andreassen et al., 2013; Hanson & Gottesman, 
2005; Harris et al., 2008; Malaspina, 2013; Meier et al., 2015; Meier et al., 2013; 
Schmidt-Kastner, van Os, Esquivel, Steinbusch, & Rutten, 2012), and cannabis has 
known effects on the vasculature (Hall & Degenhardt, 2014; Jacobus et al., 2012; 
Jouanjus, Lapeyre-Mestre, Micallef, & French Assoc Regional Abuse, 2014; Thomas, 
Kloner, & Rezkalla, 2014; Wolff et al., 2014). The present study aims to test whether 
vascular risk is detectable in individuals with subclinical symptoms of psychosis, and 
whether cannabis use accentuates that vascular risk. 
There are at least four lines of evidence suggesting that individuals with psychosis 
may have a vascular vulnerability that predisposes them to psychotic illness. The first line 
of evidence relates to the robust finding that individuals with schizophrenia are more 
likely than members of the general population to develop cardiovascular diseases 
(Hennekens, Hennekens, Hollar, & Casey, 2005; McCreadie, 2003). Results from a 
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population-based study spanning two decades showed that adults with schizophrenia 
were approximately two times more likely to die of cardiovascular disease than members 
of the general population (Osby, Correia, Brandt, Ekbom, & Sparen, 2000). This 
increased risk has been only partially attributed to lifestyle factors, such as tobacco use 
and poor diet, and antipsychotic medication (Fan, Wu, Shen, Ji, & Zhan, 2013; Osborn et 
al., 2007). Studies of antipsychotic-naive, first-episode psychosis patients suggest that 
cardiovascular risk may be related to the initiating vulnerability to schizophrenia. For 
example, first-episode psychosis patients and their unaffected relatives have increased 
rates of cardiovascular risks (Mitchell et al., 2013; Ryan, Collins, & Thakore, 2003; 
Spelman, Walsh, Sharifi, Collins, & Thakore, 2007). A recent study also showed that 
several genetic loci associated with cardiovascular risks are also associated with 
psychosis (Andreassen et al., 2013), consistent with the implication that cardiovascular 
risk is not simply a consequence of illness. These findings suggest that individuals with 
schizophrenia may have an underlying vascular vulnerability that is unrelated to 
treatment and lifestyle factors.  
The second line of evidence implicating vascular risk in the pathogenesis of 
psychosis is recent research documenting retinal microvascular abnormalities, an 
indicator of subclinical cardiovascular risk, in individuals with schizophrenia (Meier et 
al., 2013). Because the microvessels in the retina are similar in structure and function to 
microvessels in the brain and heart, they provide a proxy measure of the health of 
cerebral and coronary microvessels (Patton et al., 2005). In a population-based 
longitudinal study, Meier and colleagues (2013) compared the diameter of the retinal 
venules (small veins) in individuals with schizophrenia to medical and psychiatric 
 3 
controls. Individuals with schizophrenia had substantially wider venules than did 
individuals with pre-diabetes/diabetes, high blood pressure, persistent tobacco 
dependence, and persistent depression. This finding is important because prior research 
has shown that wider retinal venules predict cardiovascular disease, stroke, and dementia, 
even after controlling for other cardiovascular risk factors including smoking, 
hypertension, high cholesterol, diabetes, and obesity (Ikram et al., 2006; Ikram, Ong, 
Cheung, & Wong, 2013; McGeechan et al., 2009; Sun, Wang, Mackey, & Wong, 2009). 
Findings could not be explained by antipsychotic medication, as effect sizes were similar 
among the subgroup of individuals with schizophrenia who had not taken antipsychotic 
medication in the prior year. The study also showed that children with psychosis 
symptoms had wider venules as adults, suggesting that the pathological mechanisms 
underlying wider venules in schizophrenia may begin in childhood.  
As a follow-up, Meier and colleagues (2015) used retinal imaging to examine 
retinal venular diameter in adolescent and young adult twins discordant for psychotic-like 
experiences. As in the earlier study, individuals who reported psychotic-like experiences 
had wider venules than controls. Interestingly, the unaffected co-twins of individuals with 
psychotic-like experiences had retinal venular diameters that were intermediate between 
probands and controls. These differences in the venules of young adults with 
subthreshold psychosis symptoms, along with a similar but attenuated pattern in their 
unaffected co-twins, suggest that wide venules may be a marker of underlying vascular 
risk rather than a product of illness and treatment (Meier et al., 2015).  
The third line of evidence comes from research demonstrating that patients with 
schizophrenia show altered patterns of cerebral blood flow and blood volume, which 
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have been hypothesized to arise from vascular abnormalities (Bachneff, 1996; Cohen, 
Yurgelun-Todd, & Renshaw, 1995). The fourth line of evidence is that some individuals 
with schizophrenia, and their unaffected relatives, demonstrate a minimal or absent 
response to niacin skin flush challenges, suggesting an impairment in vasodilation 
(Hudson, Lin, Cogan, Cashman, & Warsh, 1997; Lien et al., 2013; Ward, Sutherland, 
Glen, & Glen, 1998). Taken together, these four pieces of evidence suggest an underlying 
vascular vulnerability in individuals with psychosis. 
Such a vascular vulnerability may be exacerbated by cannabis use. Cannabinoid 
receptors are widely distributed in vascular and endothelial cells (Liu et al., 2000; Rajesh 
et al., 2007; Sugiura et al., 1998). A recent review of in-vitro animal and human studies 
found that various cannabinoids, including tetrahydrocannabinol (THC, the primary 
psychoactive ingredient in cannabis), have both vasorelaxant and vasoconstrictive effects, 
depending on the type and location of the receptor targeted (Stanley & O'Sullivan, 2014). 
Human studies of acute vascular effects of cannabis consumption generally find increases 
in heart rate and cardiac output and modest increases in blood pressure immediately 
following cannabis inhalation (Aryana & Williams, 2007; Jones, 2002). Additionally, 
studies report acute increases in postural hypotension, or a decrease in blood pressure 
when moving from a sitting to a standing position, which can result in dizziness and 
fainting (Jones, 2002; Sidney, 2002). Several early studies also demonstrated increased 
cerebral blood flow (CBF) (Mathew et al., 1999; Mathew, Wilson, Coleman, Turkington, 
& DeGrado, 1997; Mathew, Wilson, & Tant, 1989) and glucose metabolism (Volkow et 
al., 1996) in regular cannabis users immediately following cannabis consumption. These 
findings suggest an acute effect of cannabis use on the vasculature. 
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Furthermore, neuroimaging studies suggest a potential effect of chronic cannabis 
use on the cerebral vasculature. Regular cannabis users have lower resting levels of 
cerebral blood flow (CBF) compared with controls (Lundqvist, Jonsson, & Warkentin, 
2001). Moreover, patterns of blood flow immediately following cannabis intake differ 
among experienced and inexperienced cannabis users, suggesting that chronic cannabis 
use alters vascular function. Experienced users show dose-related increases in CBF 
immediately following cannabis administration (Mathew, Wilson, Humphreys, Lowe, & 
Weithe, 1993; Mathew et al., 1989), whereas inexperienced users show a reduction in 
CBF (Mathew et al., 1989). Experienced users also show a decrease in CBF in the period 
immediately following cessation of cannabis use, perhaps suggesting a withdrawal effect 
on CBF (Lundqvist et al., 2001; Herning, Better, Tate, & Cadet, 2005; Jacobus et al., 
2012; Tunving, Thulin, Risberg, & Warkentin, 1986). Whether differences persist after 
prolonged abstinence is currently unclear, however. One study found that differences in 
CBF between cannabis users and non-users persisted after prolonged abstinence (Herning 
et al., 2005) whereas two others did not (Jacobus et al., 2012; Tunving et al., 1986). 
Cannabis use has also been associated with cardiovascular events in case reports 
and observational studies. Recent reviews have concluded that cannabis users have an 
increased risk of myocardial infarction (i.e., heart attack) and stroke (Hall & Degenhardt, 
2014; Thomas et al., 2014; Volkow, Baler, Compton, & Weiss, 2014). The association 
between cannabis use and myocardial infarction appears to be attributable to the acute 
effects of cannabis (Thomas et al., 2014), with one study reporting that risk of 
myocardical infarction was 4.8 times greater within one hour of smoking (Mittleman, 
Lewis, Maclure, Sherwood, & Muller, 2001). Recent reports have indicated that cannabis 
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use can induce myocardial infarction and stroke in otherwise healthy young cannabis 
users with limited cardiovascular risk factors (Jouanjus et al., 2014). Furthermore, a study 
demonstrating myocardial infarction following consumption of the synthetic cannabinoid 
K2, which contains an analogue of THC, indicates that cardiovascular events may be 
caused by psychoactive cannabinoids rather than one of the 500 other chemical 
components of the marijuana plant (Mir, Obafemi, Young, & Kane, 2011).  
In light of these findings, I submit that cannabis use may exacerbate vascular 
problems in individuals prone to psychosis. Because cannabis may have deleterious 
effects on the vasculature, chronic use could result in repeated “hits” to an already 
vulnerable vascular system (Malone et al., 2010). Such a “hit” process could subtly but 
chronically deprive the brain of oxygen and nutrients and lead to the development of 
psychosis symptoms in those with pre-existing vascular vulnerability (Hanson & 
Gottesman, 2005). Thus, the present study aimed to test whether cannabis use 
exacerbates retinal vessel abnormalities in young adults with psychotic-like experiences. 
I tested four hypotheses. First, I tested whether individuals with psychotic-like 
experiences have wider retinal venules than individuals without psychotic-like 
experiences, thereby replicating previous findings (Meier et al., 2015; Meier et al., 2013). 
Second, I tested whether cannabis users have wider retinal venules than non-users, given 
previous findings linking cannabis and neurovascular alterations (Herning et al., 2005; 
Jacobus et al., 2012). Third, I tested whether individuals with psychotic-like experiences 
who also use cannabis regularly have the widest retinal venules, based upon a “hit” 
model by which cannabis use accentuates vascular abnormalities related to psychosis 
(Malone et al., 2010). Fourth, I tested whether the associations between wider venules, 
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cannabis use, and psychotic symptoms held after controlling for other risk factors such as 
tobacco and alcohol use, BMI, blood pressure, and depression and anxiety symptoms.   
Method 
Participants 
Participants were 108 college students from a large southwestern university. 
Students enrolled in introductory psychology courses were screened for psychotic-like 
experiences using the Yale University PRIME Screening Test (Miller, Cicchetti, 
Markovich, McGlashan, & Woods, 2004). Students who scored in the top 10% of the 
distribution of this screen (corresponding to scores roughly 1.5 standard deviations above 
the mean) were recruited, as were students who scored in the bottom 10% of the 
distribution. Students then underwent a phone screening to assess cannabis use. Students 
who reported less than 20 lifetime cannabis uses and no use in the past month were 
recruited as non-users. Students who reported at least 40 lifetime cannabis uses and use in 
the past month were recruited as cannabis users. Both users and non-users were then 
invited to the laboratory to complete questionnaires and undergo retinal imaging. Of the 
108 participants, 7 were excluded from analyses as one participant had ungradable retinal 
images and 6 participants reported low-moderate cannabis use, preventing them from 
being classified as users or non-users. 
Of the 101 participants included in analyses, 45.54% (n=46) were women and 
54.46% (n=55) were men. Participants were a mean age of 19.37 years (SD=1.93), and 
73.27% of participants were White, 13.86% were Hispanic, 4.95% were African-
American, 3.96% were Asian, and 3.96% identified as “Other.” 
Measures 
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Psychotic-like Experiences (PLEs). 
The Yale PRIME screen is a 12-item self-report questionnaire that asks 
participants to report on whether they have had unusual subjective experiences (Miller et 
al., 2004). Participants rate whether they have experienced each item on a 0-6 Likert 
scale (0=definitely disagree; 6=definitely agree). Example items are: “I think that I may 
hear my own thoughts being said out loud,” “I think that I might be able to predict the 
future,” and “I wonder if people may be planning to hurt me or even may be about to hurt 
me.” The total score is computed by summing the items. The Yale PRIME screen has 
demonstrated good convergent and discriminant validity as well as high reliability in a 
college student sample (Kline et al., 2012). For the current study, I categorized 
participants with a total score of 40 or higher as positive for psychotic-like experiences 
because individuals with these scores represented the top 10% of the screening-sample 
distribution. Participants with a total score of less than 6 were classified as negative for 
psychotic-like experiences because these scores represented the bottom 10% of the 
screening-sample distribution.  
Cannabis Use. 
Participants self-reported their lifetime frequency of cannabis use. Response 
options were: 0 = never, 1 = one or two times, 2 = three to nine times, 3 = 10 to 19 times, 
4 = 20 to 39 times, 5 = 40 to 99 times, 6 = 100 to 199 times, 7 = 200 to 500 times, and 8 
= more than 500 times. Participants also reported whether they used cannabis in the 24 
hours prior to coming to the laboratory. The prevalence of past 24-hour cannabis use in 
the sample was 21.78%. 
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Participants were classified as cannabis users if they had used cannabis 40 or 
more times and as non-users if they had used fewer than 20 times, based on the original 
recruitment process that aimed to capture users and non-users. However, I conducted 
sensitivity analyses using several different methods for categorizing cannabis users and 
non-users, and results were unchanged (see Supplement 1). In addition, I ran analyses 
controlling for past 24-hour cannabis use to test whether the acute effects of cannabis 
might explain my findings, and results were unchanged (see Supplement 2). 
Retinal Imaging. 
Digital fundus photographs were taken at our laboratory after 5 minutes of dark 
adaptation. The same camera (Canon CR-2 with an EOS 60D backing) was used for all 
photographs, and each participant had both eyes photographed. I report results for 
measurements of the right eye, as measurements for the right and left eye are highly 
correlated (Leung et al., 2003). In the case of one participant whose right eye image was 
ungradable, the left eye image was used instead. Retinal photographs were graded at the 
Singapore Eye Research Institute, National University of Singapore by trained graders 
who were blind to participant characteristics. Graders used semi-automated computer 
software (Singapore “I” Vessel Assessment [SIVA], version 3.0) to measure retinal 
vessel diameters, following a standardized protocol with high intergrader reliability 
(Cheung et al., 2010). Measurements were made for arterioles and venules where they 
pass through a region located 0.50–2.00 disk diameters from the optic disk margin 
(Cheung et al., 2010). Vessel diameters refer to the internal space of the vessels and were 
based on the six largest arterioles and venules passing though this region. These 
diameters were summarized using the revised Knudtson-Parr-Hubbard formula as central 
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retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) (Knudtson 
et al., 2003). Retinal vessel diameters are reported in micrometers (μm). The mean 
venular diameter for the sample was 217.56 μm (SD=15.42) and the mean arteriolar 
diameter was 156.29 μm (SD=10.32). The correlation between venules and arterioles was 
0.54. Mean venular and arteriolar diameter in the current sample were generally similar 
to corresponding mean diameters reported in population-based samples (Ikram et al., 
2004; Kim et al., 2011; Meier et al., 2014; Meier et al., 2013; Wong et al., 2006). See 
Supplemental Table 1 for mean arteriolar and venular diameters in each of these 
previous studies. 
Covariates 
Blood pressure, body mass index, tobacco use, alcohol use, depression symptoms, 
and anxiety symptoms were considered as covariates in analyses because these factors 
have been shown to be associated with psychotic-like experiences (Degenhardt, Hall, & 
Lynskey, 2001; Foley et al., 2013; Johns et al., 2004; Kelleher & Cannon, 2011; Morgan 
et al., 2014), cannabis use (Badiani et al., 2015; Wechsler & McFadden, 1979), and 
retinal vessel diameter (Ikram, Ong, et al., 2013; Klag et al., 1989; Meier et al., 2014; 
Meier et al., 2015; Meier et al., 2013; Sun et al., 2009).  
Blood Pressure. 
Blood pressure was assessed using an Omron HEM 705 CP auto-inflate blood 
pressure monitor. I created a dichotomous variable for high blood pressure that included 
individuals with hypertension and prehypertension based on American Heart Association 
standards (Chobanian et al., 2003). First, I took the average of three successive blood 
pressure measurements for systolic and diastolic pressure. Then, I classified participants 
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as having high blood pressure if they had a mean systolic blood pressure of ≥ 120, or if 
they had a mean diastolic blood pressure of ≥ 80. Fourteen participants (13.86% of the 
sample) were classified as having high blood pressure. 
Body Mass Index. 
I used participants’ self-reported height and weight to calculate body mass index 
(BMI). Using a subsample of 66 participants, I validated these estimates of BMI against 
estimates from a non-invasive, leg-to-leg bioelectrical impedance analysis (BIA) monitor 
(Tanita SC331S). The BIA monitor measures body mass index by determining 
impedance to a small electrical current sent through the body. Accuracy of the monitor 
for weight is ±0.2lb, and ± 2% for impedance measurement. The correlation between 
estimates of BMI was r=.98. Mean BMI for the sample was 23.85 (SD=5.26). 
Tobacco Use. 
Participants reported on their tobacco use. Participants were classified as tobacco 
smokers if they currently smoked cigarettes or if they had ever smoked cigarettes 
regularly. The prevalence of tobacco smoking in the sample was 23.47%.  
Alcohol Use. 
Participants self-reported lifetime alcohol use by responding to the question, 
“During your life, on how many days have you had at least one drink of alcohol?” Of 
participants in the sample, 6.93% reported never having used alcohol, 7.92% reported one 
or two days of use, 14.85% reported three to nine days of use, 9.90% reported 10 to 19 
days of use, 12.87% reported 20 to 39 days of use, 13.83% reported 40 to 99 days of use, 
and 30.69% reported 100 or more days of use.  
Depression Symptoms.  
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Depression symptoms were assessed using the Center for Epidemiologic Studies 
Depression Scale (CES-D), a 20-item scale with total scores ranging from 0-60 
developed for use in non-clinical populations (Radloff, 1977). The CES-D has been 
found to be reliable across ethnic groups (Roberts, 1980) and has good sensitivity and 
specificity in college student samples (Shean & Baldwin, 2008). Mean total CES-D score 
for the sample was 20.67 (SD=13.11). 
Anxiety Symptoms. 
Anxiety symptoms were assessed using the anxiety subscale from the Depression 
and Anxiety Stress Scale (DASS) (Lovibond & Lovibond, 1995). The subscale is 
composed of 14 items, with each item rated on a 4-point Likert scale, yielding total 
scores ranging from 0-42. The DASS shows excellent reliability and adequate convergent 
and discriminant validity (Crawford & Henry, 2003). The mean DASS anxiety score for 
the sample was 4.30 (SD=5.68). 
Statistical Analyses 
I used analysis of variance (ANOVA) to test differences in retinal arteriolar and 
venular diameter across four groups: a group with no psychosis symptoms and no 
cannabis use (PLE-/CAN-; n=27); a group with cannabis use but no psychosis symptoms 
(PLE-/CAN+; n=9); a group with psychosis symptoms but no cannabis use (PLE+/CAN-; 
n=32); and a group with both psychosis symptoms and cannabis use (PLE+/CAN+; 
n=33).  
To test whether cannabis use was associated with wider retinal venules, I tested 
the main effect of cannabis use on venular diameter. That is, I estimated mean venular 
diameter for the cannabis-using groups (i.e., the mean pooled across PLE-/CAN+ and 
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PLE+/CAN+ groups) and compared this mean to the mean for the non-using groups (i.e., 
the mean pooled across the PLE-/CAN- and PLE+/CAN- groups). To test whether 
psychotic-like experiences were associated with wider venules, I tested the main effect of 
psychotic-like experiences on retinal venular diameter. That is, I estimated mean venular 
diameter for the groups with psychotic-like experiences (PLE+/CAN- and PLE+/CAN+) 
and compared this mean to the mean for the groups without psychotic-like experiences 
(PLE-/CAN- and PLE-/CAN+). Finally, I tested for an interaction between cannabis use 
and psychotic-like experiences. That is, I tested whether cannabis use had a greater effect 
on mean venular diameter for people with psychotic-like experiences than for people 
without psychotic-like experiences (i.e., whether the difference between the means of 
PLE-/CAN- and PLE-/CAN+ was smaller than the difference between the means of 
PLE+/CAN- and PLE+/CAN+). I then repeated all analyses for arteriolar diameter.  
Next, I used analysis of covariance (ANCOVA) to test whether the observed 
effects were robust to control for covariates. To determine which of the theoretically-
relevant variables should be included as covariates in the ANCOVAs, I examined the 
correlations between covariates and independent and dependent variables. Potential 
covariates that were associated with both the independent variables and the dependent 
variable were incorporated into analyses. I used Pearson product moment correlations to 
assess the associations between pairs of continuous variables, Pearson point-biserial 
correlations to assess the associations between continuous and dichotomous variables, 
and chi-square tests to assess the associations between pairs of dichotomous variables. As 
shown in Table 2, none of the potential covariates were related to both the dependent 
variable and an independent variable, indicating that these variables could not have 
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confounded the results of the original ANOVAs. However, for thoroughness, I included 
each of these variables in a series of ANCOVAs to ensure that results did not change.  
Prior to running all analyses, I conducted diagnostic tests to determine whether 
the ANOVA assumptions of homogeneity of variance and normal distribution of 
dependent variable scores for each group had been met. The Levene’s test of 
homogeneity of variance was not significant for venules (F=0.28, p=.84) or for arterioles 
(F=1.39, p=.25), indicating that the homogeneity of variance assumption was met for 
both dependent variables. To examine the distributions of the dependent variables for 
each group, I examined box-plot graphics and histograms. There were no obvious outliers 
on venular diameter or arteriolar diameter (i.e., there were no observed scores that 
differed from the mean by more than three standard deviations). However, one 
observation for arteriolar diameter and one observation for venular diameter were nearly 
3 standard deviations above each respective mean. To ensure that these observations did 
not unduly influence results, I repeated all analyses twice: once with these scores 
excluded and once with these scores recoded to be equal to the next highest observed 
score. Results remained unchanged and details are presented in Supplement 3. Skew and 
kurtosis of venular and arteriolar diameter scores were between -1 and 1 within each 
group (with the exception of the PLE-/CAN+, for which kurtosis of arteriolar diameter 
was -1.39). The Kolmogorov-Smirnov test revealed that the skew and kurtosis of retinal 
venular and arteriolar diameter were not outside acceptable ranges within each group 
(p>.15 on both variables for every group).  
I also performed diagnostic tests to determine whether the ANCOVA assumption 
of homogeneity of regression was met. Because this assumption requires the same 
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association between the covariate and the dependent variable for all groups, I tested for 
interactions between each covariate and cannabis use status and for interactions between 
each covariate and psychotic-like experiences group status in predicting each dependent 
variable. There were no significant interactions, indicating that the homogeneity of 
regression assumption was satisfied for all covariates.  
Results 
Descriptive statistics for all study variables are presented for each group in Table 
1. This table shows that, as intended, psychotic-like experiences scores were higher for 
the groups classified as having psychotic-like experiences than for the groups classified 
as not having psychotic-like experiences. Likewise, means for lifetime cannabis use were 
higher for the cannabis-using groups than for the groups that did not use cannabis.  
To test my hypotheses, I conducted a two-factor ANOVA predicting venular 
diameter from cannabis use and psychotic-like experiences. I included the main effects of 
psychotic-like experiences and cannabis use and the interaction between psychotic-like 
experiences and cannabis use in the model. The interaction term was not statistically 
significant (F(1, 97)=0.46, p=.50), indicating that there was not a statistical interaction 
between cannabis use and psychotic-like experiences in predicting venular diameter. 
Therefore, I interpreted the main effects of psychotic-like experiences and cannabis use 
on venular diameter. Figure 1 shows that there was no statistically significant difference 
in venular diameter between groups with (M=218.08, SD=15.09) versus without 
psychotic-like experiences (M=216.61, SD=16.18) (F(1, 97)=0.01, p=.93). Figure 2 
shows that there was no statistically significant difference in venular diameter for 
cannabis users (M=218.41, SD=14.31) versus non-users (M=216.95, SD=16.26) (F(1, 
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97)=0.37, p=.54). Because there were no significant effects of psychotic-like experiences, 
cannabis use, or their interaction on venular diameter, I did not test models including 
covariates. 
I next performed a two-factor ANOVA predicting arteriolar diameter from 
psychotic-like experiences and cannabis use. I included the main effects of psychotic-like 
experiences and cannabis use and the interaction between psychotic-like experiences and 
cannabis use in the model. The interaction term was not statistically significant (F(1, 
97)=1.33, p=.25), which indicated that there was little evidence of a statistical interaction 
between psychotic-like experiences and cannabis use in predicting arteriolar diameter. 
Because the interaction was not statistically significant, I interpreted the main effects of 
psychotic-like experiences and cannabis use on arteriolar diameter. Figure 3 shows that 
there was no statistically significant difference in arteriolar diameter between groups with 
(M=157.07, SD=10.96) versus without (M=154.88, SD=9.03) psychotic-like experiences 
(F(1, 97)=0.00, p=.97). Figure 4 shows that cannabis users had statistically significantly 
greater mean arteriolar diameter (M=159.10, SD=9.94) than did non-users (M=154.29, 
SD=10.20) (F(1, 97)=5.99, p=.016). There was a mean difference of 0.47 standard 
deviation units on arteriolar diameter between cannabis users and non-users, which is 
commensurate with a medium effect size (Cohen, 1988).  
I next conducted a series of analyses of covariance to determine whether the 
association between cannabis use and arteriolar diameter was robust to control for 
potential confounds. The main effect of cannabis use was robust to controls for sex, 
psychotic-like experiences, tobacco use, alcohol use, BMI and blood pressure, and 
depression and anxiety symptoms. The final ANCOVA with all covariates included 
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indicated statistically significant mean differences in arteriolar diameter between 
cannabis users and non-users (F(1, 86) = 11.30, p = .001), such that cannabis users had 
wider retinal arterioles than did non-users. Figure 5 shows the adjusted means for each 
ANCOVA, with each set of additional covariates included. 
Finally, to most rigorously control for Type I Errors, I applied a Bonferroni 
correction to the alpha level of the significant finding that cannabis users had wider 
arterioles than did non-users. My full set of analyses included six tests (testing for 
differences between cannabis use groups, psychotic-like experiences groups, and their 
interaction for both arterioles and venules). After correcting for these multiple tests, the 
new threshold for statistical significance was p<.008. Using this more stringent threshold, 
the difference in mean arteriolar diameter between cannabis users and non-users with all 
covariates included in the model remained statistically significant (p=.001). 
Discussion 
The current study aimed to test the hypotheses that psychotic-like experiences and 
cannabis use are associated with wider retinal vessels, and that individuals with 
psychotic-like experiences who also use cannabis have the widest retinal vessels. In this 
college student sample, there were no significant differences in venular or arteriolar 
diameter between participants who endorsed psychotic-like experiences and those who 
did not. This is inconsistent with past research that has found wider retinal venules in 
individuals with schizophrenia and in individuals with psychotic symptoms, as compared 
with healthy controls (Meier et al., 2015; Meier et al., 2013). However, my results may 
not be directly comparable with these past findings due to methodological differences 
between the studies. For example, the current study sampled participants from a college 
 18 
student population, whereas one previous study involved adults diagnosed with 
schizophrenia (Meier et al., 2013). Because of the greater level of psychopathology in the 
previous study, as well as the older age of the participants (38 years), microvascular 
abnormalities may only be apparent in chronic, severe schizophrenia. This might suggest 
that microvascular abnormalities in schizophrenia are a result of the disease process 
rather than indicative of an underlying liability to psychosis.  
However, this interpretation is at odds with the results of a second study showing 
wider retinal venules among young adults with psychotic-like symptoms and their 
unaffected relatives as compared with healthy controls (Meier et al., 2015). An alternate 
explanation, therefore, is that the psychosis screening measure used in the current study 
failed to identify individuals with severe psychotic-like experiences. Whereas the current 
study employed a brief self-report measure of psychotic-like experiences, Meier et al. 
(2013) used more thorough assessments. Their assessment, which counted only 
hallucinations and delusions as psychotic symptoms, may have captured more severe 
levels of psychopathology than did the screener used in the current study. Indeed, the cut-
off used to recruit high risk individuals into the current study (a Yale PRIME score in the 
top 10% of the screening distribution) may have captured many participants with 
relatively normative experiences.  
Additionally, the current study used a college student sample with demographic 
characteristics that may not be representative of a community sample. For example, 
nearly 80% of the current sample was from upper middle class families. Given these 
characteristics, the results may not be directly comparable with those of studies using 
samples with greater heterogeneity in health, socioeconomic status, and other 
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characteristics associated with well-being (Meier et al., 2015; Meier et al., 2013). 
Because the participants in the current study were all enrolled in college courses, it is also 
reasonable to believe that they may have been, on average, higher-functioning and 
experiencing less severe psychopathology than participants with psychotic-like 
experiences drawn from a community sample. Moreover, severe functional impairment 
may have caused individuals at the highest risk of developing a psychotic disorder to 
drop out of school, preventing them from participating in the study.  
In examining the association between cannabis use and retinal vessel diameter, I 
found that participants who used cannabis had wider retinal arterioles than did 
participants who did not use cannabis. This result is similar to findings in older adults of 
wider retinal arterioles in tobacco smokers as compared with non-smokers (Daien et al., 
2013; Ikram et al., 2004; Kifley et al., 2007; Klein, Klein, Knudtson, Wong, & Tsai, 
2006; Wong et al., 2006). However, these studies also tend to find similar or stronger 
associations of tobacco use with wider venules (Ikram et al., 2004; Kifley et al., 2007). It 
is unclear why I found that cannabis use is associated with wider arterioles but not wider 
venules. One explanation may be that cannabis and tobacco have slightly different effects 
on the retinal microcirculation. An alternative explanation is that most research on retinal 
vessels and tobacco use has been conducted in older adult populations with greater 
exposure to tobacco. The participants in our study were young adults, with relatively low 
exposure to cannabis. The finding of wider arterioles in cannabis users in the current 
sample of young, otherwise healthy adults is in line with the hypothesis that wide 
arterioles reflect the earliest stages of pathology, and that, with increases in exposure to 
cannabis, wider venules may also become apparent.  
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In the current study, the difference in arteriolar diameter between cannabis users 
and non-users remained significant even when controlling for potential confounds, 
including tobacco use. Furthermore, the relative youth and low prevalence of cigarette 
smoking (23.47% of participants smoked regularly at some point in their lives), high 
blood pressure (13.86% of participants had hypertension or prehypertension), and obesity 
(9.90% of participants) in this sample minimize disease-related explanations for arteriolar 
widening. Thus, the current evidence suggests that wide retinal arterioles may be related 
specifically to cannabis use rather than comorbid tobacco use, hypertension, or obesity. 
Although the cross-sectional nature of the current study precludes causal inferences, this 
finding of wider arterioles among cannabis users is consistent with existing evidence that 
cannabis use may affect vascular function (Herning et al., 2005; Jacobus et al., 2012; 
Lundqvist et al., 2001; Mathew et al., 1993; Mathew et al., 1989; Tunving et al., 1986).  
This finding advances scientific understanding as the first evidence, to my 
knowledge, of a microvascular difference between cannabis users and non-users. This 
difference may be especially important because wide arterioles have been linked to heart 
failure, diabetes, and retinopathy (Kifley et al., 2007; Nguyen et al., 2008; Phan et al., 
2015; Rogers et al., 2008; Yau et al., 2012). Although the mechanism underlying these 
relations remains uncertain, evidence suggests that arteriolar widening reflects impaired 
autoregulation of the arterioles, or problems maintaining blood flow in response to 
changes in perfusion pressure (Alibrahim et al., 2006; Cheung et al., 2008; Gardiner, 
Archer, Curtis, & Stitt, 2007). In normal retinae, the arterioles constrict in response to 
increased blood pressure and dilate in response to decreased blood pressure (Ikram, 
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Cheung, et al., 2013). In some individuals, however, this response is impaired, and such 
impairment predicts future widening of the arterioles (Lorenzi et al., 2010).  
Given this relation, wide arterioles may be a sign of impaired autoregulation that 
can permit abnormally high or low blood flow to organs including the brain. In the 
context of high pressure, impaired autoregulation could lead to hyperperfusion, resulting 
in leakage and rupture of the capillary walls (Alibrahim et al., 2006; Gardiner et al., 
2007; Ikram, Cheung, et al., 2013; Keel, Koklanis, Vukicevic, Itsiopoulos, & Brazionis, 
2014). In the context of low pressure, impaired autoregulation could result in 
hypoperfusion and hypoxia, or an inadequate supply of oxygen and nutrients due to 
insufficient blood flow. Thus, wide arteriolar diameter in cannabis users may suggest one 
mechanism by which chronic cannabis use results in damage to the vasculature. 
However, this potential mechanism remains speculative, and experimental studies are 
needed to determine whether the relations between cannabis exposure, arteriolar 
widening, and cardiovascular consequences are indeed causal. 
The current findings must be interpreted in the context of a number of limitations 
of this study. First, the psychosis screening measure may have classified healthy 
individuals as positive for psychotic-like experiences, resulting in an attenuated effect 
size for associations between psychotic-like experiences and retinal vessel diameter. 
Relatedly, the current sample size was relatively small, and very small effects may not 
have been detectable. Second, young adults in college may differ in important ways from 
young adults not in college, limiting the generalizability of these findings. Future 
research may rectify these problems by testing these associations in larger and more 
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diverse samples, and by using more rigorous assessments of psychosis symptoms such as 
structured clinical interviews.  
Third, the cross-sectional nature of the current study precludes causal inference 
about the relation between cannabis use and arteriolar widening. One possibility is that 
arteriolar widening may be a consequence of cannabis use. However, another possibility 
is that wide arteriolar diameter is characteristic of individuals who are predisposed to 
substance abuse, such that wide arteriolar diameter precedes the onset of heavy cannabis 
use. Thus, longitudinal evidence is needed to establish the temporal precedence of 
cannabis use or arteriolar diameter to determine the direction of the effect observed in 
this study. Finally, although I controlled for several potential confounds, there remains a 
possibility that unmeasured variables related to both cannabis use and arteriolar diameter 
may be driving the association between them. 
Despite these limitations, the current findings suggest a number of promising 
directions for future research on the relation of cannabis use and cardiovascular health. 
Given the association between cannabis use and wide arterioles observed in this study, 
other designs can be used to provide further evidence for a causal role of cannabis use in 
arteriolar widening. For example, future studies might assess retinal vessel diameter in 
childhood, before the onset of substance use, to rule out the possibility that wide 
arterioles precede cannabis use. To provide further evidence of a causal relationship, twin 
studies could also be used to separate the risk posed by cannabis use from other factors. 
Comparing arteriolar diameter in monozygotic twins discordant for cannabis use would 
allow researchers to rule out shared genetic and environmental influences, strengthening 
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the theory that chronic cannabis use is causally related to changes in the 
microvasculature.  
In addition to longitudinal and twin studies, future research might test a dose-
response relation between cannabis use and arteriolar diameter. The current study 
provides evidence for mean differences in arteriolar diameter between relatively heavy 
cannabis users and non-users. Future studies including light, moderate, and heavy 
cannabis users could test a linear relation of increasing cannabis consumption and 
arteriolar widening within the cannabis-using group. Evidence for such a dose-response 
relation could provide further support for the theory that cannabis use is causally related 
to arteriolar widening (Hill, 1965).  
Finally, experimental designs could be used to provide the strongest evidence for 
a causal relation. For example, intervention studies could test whether cannabis users who 
quit in treatment show subsequent arteriolar narrowing. Such a design could provide 
evidence for a reversible effect of cannabis on the microvasculature, although null 
findings could not rule out the possibility of permanent effects of cannabis use. To test 
the effect of cannabis initiation on arteriolar diameter, researchers could use animal 
studies to manipulate cannabis exposure. In addition to testing a causal effect, such 
studies have the added potential to clarify the mechanism by which the effect occurs. For 
example, one recent study found that rats exposed to second-hand cannabis smoke 
showed acute impairment of endothelial function, a form of arterial autoregulation (Wang 
et al., 2016). Such experimental designs could be used to test chronic effects of cannabis 
exposure on arteriolar auto-regulation, future arteriolar widening, and subsequent 
pathological states. 
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In conclusion, the current study provides preliminary evidence of damage to the 
microvasculature in young adult cannabis users. Given recent changes in public policy 
that have increased the accessibility of cannabis for young adults, it is important to 
consider the potential public health consequences of widespread cannabis use. The 
current findings indicate that cannabis use may be a modifiable risk factor for poor 
cardiovascular health and that future research is needed to determine the long-term 
consequences of recreational use.  
 25 
References 
Alibrahim, E., Donaghue, K. C., Rogers, S., Hing, S., Jenkins, A. J., Chan, A., & Wong, 
T. Y. (2006). Retinal vascular caliber and risk of retinopathy in young patients 
with type 1 diabetes. Ophthalmology, 113(9), 1499-1503. 
doi:10.1016/j.ophtha.2006.05.009 
 
Andreassen, O. A., Djurovic, S., Thompson, W. K., Schork, A. J., Kendler, K. S., 
O'Donovan, M. C., . . . Psychiatric Genomics, C. (2013). Improved Detection of 
Common Variants Associated with Schizophrenia by Leveraging Pleiotropy with 
Cardiovascular-Disease Risk Factors. American Journal of Human Genetics, 
92(2), 197-209. doi:10.1016/j.ajhg.2013.01.001 
 
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002). 
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective 
study. British Medical Journal, 325(7374), 1212-1213. 
doi:10.1136/bmj.325.7374.1212 
 
Aryana, A., & Williams, M. A. (2007). Marijuana as a trigger of cardiovascular events: 
Speculation or scientific certainty? International Journal of Cardiology, 118(2), 
141-144. doi:10.1016/j.ijcard.2006.08.001 
 
Bachneff, S. A. (1996). Regional cerebral blood flow in schizophrenia and the local 
circuit neurons hypothesis. Schizophrenia Bulletin, 22(1), 163-182. 
doi: 10.1093/schbul/22.1.163 
 
Badiani, A., Boden, J., Pirro, S., Fergusson, D., Horwood, J., & Harold, G. (2015). 
Tobacco smoking and cannabis use in a longitudinal birth cohort: Evidence of 
reciprocal causal relationships. Drug and Alcohol Dependence, 150, 69-76. 
http://dx.doi.org/10.1016/j.drugalcdep.2015.02.015 
 
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., . . . Craig, 
I. W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult 
psychosis by a functional polymorphism in the catechol-O-methyltransferase 
gene: Longitudinal evidence of a gene X environment interaction. Biological 
Psychiatry, 57(10), 1117-1127. doi:10.1016/j.biopsych.2005.01.026 
 
Chacko, B. G., Edwards, M. S., Sharrett, A. R., Qureshi, W. T., Klein, B. E. K., Klein, 
R., . . . Soliman, E. Z. (2015). Microvasculature and incident atrioventricular 
conduction abnormalities in the Multi-Ethnic Study of Atherosclerosis (MESA). 
Vascular Medicine, 20(5), 417-423. doi:10.1177/1358863x15586475 
 
Cheung, C. Y. L., Hsu, W., Lee, M. L., Wang, J. J., Mitchell, P., Lau, Q. P., . . . Wong, T. 
Y. (2010). A New Method to Measure Peripheral Retinal Vascular Caliber over 
 26 
an Extended Area. Microcirculation, 17(7), 495-503. doi:10.1111/j.1549-
8719.2010.00048.x 
 
Cheung, N., Rogers, S. L., Donaghue, K. C., Jenkins, A. J., Tikellis, G., & Wong, T. Y. 
(2008). Retinal arteriolar dilation predicts retinopathy in adolescents with type 1 
diabetes. Diabetes Care, 31(9), 1842-1846. doi:10.2337/dc08-0189 
 
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., 
. . . Natl High Blood Pressure Educ, P. (2003). The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure - The JNC 7 Report. Jama-Journal of the American Medical 
Association, 289(19), 2560-2572. doi:10.1001/jama.289.19.2560 
 
Cohen, B. M., Yurgelun-Todd, D., & Renshaw, P. F. (1995). Abnormalities of cerebral 
vascular distribution in schizophrenia. Schizophrenia Research, 15(1-2), 80-80. 
doi:10.1016/0920-9964(95)95251-4 
 
Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences (2nd ed.). 
Hillsdale, New Jersey: Laurence Erlbaum Associates. 
 
Crawford, J. R., & Henry, J. D. (2003). The Depression Anxiety Stress Scales (DASS): 
Normative data and latent structure in a large non-clinical sample. British Journal 
of Clinical Psychology, 42, 111-131. doi:10.1348/014466503321903544 
 
Daien, V., Carriere, I., Kawasaki, R., Cristol, J. P., Villain, M., Fesler, P., . . . Delcourt, 
C. (2013). Retinal Vascular Caliber Is Associated with Cardiovascular 
Biomarkers of Oxidative Stress and Inflammation: The POLA Study. Plos One, 
8(7). doi:10.1371/journal.pone.0071089 
 
Degenhardt, L., Hall, W., & Lynskey, M. (2001). Alcohol, cannabis and tobacco use 
among Australians: a comparison of their associations with other drug use and use 
disorders, affective and anxiety disorders, and psychosis. Addiction, 96(11), 1603-
1614. doi:10.1046/j.1360-0443.2001.961116037.x 
 
Fan, Z. X., Wu, Y. Y., Shen, J., Ji, T., & Zhan, R. Y. (2013). Schizophrenia and the risk 
of cardiovascular diseases: A meta-analysis of thirteen cohort studies. Journal of 
Psychiatric Research, 47(11), 1549-1556. doi:10.1016/j.jpsychires.2013.07.011 
 
Fergusson, D. M., Horwood, L. J., & Swain-Campbell, N. R. (2003). Cannabis 
dependence and psychotic symptoms in young people. Psychological Medicine, 
33(1), 15-21. doi:10.1017/s0033291702006402 
 
Foley, D. L., Mackinnon, A., Watts, G. F., Shaw, J. E., Magliano, D. J., Castle, D. J., . . . 
Galletly, C. A. (2013). Cardiometabolic Risk Indicators That Distinguish Adults 
 27 
with Psychosis from the General Population, by Age and Gender. Plos One, 
8(12). doi:10.1371/journal.pone.0082606 
 
Gardiner, T. A., Archer, D. B., Curtis, T. M., & Stitt, A. W. (2007). Arteriolar 
involvement in the microvascular lesions of diabetic retinopathy: Implications for 
pathogenesis. Microcirculation, 14(1), 25-38. doi:10.1080/10739680601072123 
 
Hall, W., & Degenhardt, L. (2014). The adverse health effects of chronic cannabis use. 
Drug Testing and Analysis, 6(1-2), 39-45. doi:10.1002/dta.1506 
 
Hanson, D. R., & Gottesman, II. (2005). Theories of schizophrenia: a genetic-
inflammatory-vascular synthesis. Bmc Medical Genetics, 6. doi:10.1186/1471-
2350-6-7 
 
Harris, L. W., Wayland, M., Lan, M., Ryan, M., Giger, T., Lockstone, H., . . . Bahn, S. 
(2008). The Cerebral Microvasculature in Schizophrenia: A Laser Capture 
Microdissection Study. Plos One, 3(12). doi:10.1371/journal.pone.0003964 
 
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia 
and increased risks of cardiovascular disease. American Heart Journal, 150(6), 
1115-1121. doi:10.1016/j.ahj.2005.02.007 
 
Henquet, C., Krabbendam, L., Spauwen, J., Kaplan, C., Lieb, R., Wittchen, H. U., & van 
Os, J. (2005). Prospective cohort study of cannabis use, predisposition for 
psychosis, and psychotic symptoms in young people. British Medical Journal, 
330(7481), 11-14. doi:10.1136/bmj.38267.664086.63 
 
Herning, R. I., Better, W. E., Tate, K., & Cadet, J. L. (2005). Cerebrovascular perfusion 
in marijuana users during a month of monitored abstinence. Neurology, 64(3), 
488-493. http://dx.doi.org/10.1212/01.WNL.0000150882.69371.DD 
 
Hill, A. B. (1965). The environment and disease: association or causation? Proceedings 
of the Royal society of Medicine, 58(5), 295-300. 
 
Hudson, C. J., Lin, A., Cogan, S., Cashman, F., & Warsh, J. J. (1997). The niacin 
challenge test: Clinical manifestation of altered transmembrane signal 
transduction in schizophrenia? Biological Psychiatry, 41(5), 507-513. 
doi:10.1016/s0006-3223(96)00112-6 
 
Ikram, M. K., Cheung, C. Y., Lorenzi, M., Klein, R., Jones, T. L. Z., Wong, T. Y., & 
Retinal, N. J. W. (2013). Retinal Vascular Caliber as a Biomarker for Diabetes 
Microvascular Complications. Diabetes Care, 36(3), 750-759. doi:10.2337/dc12-
1554 
 
 28 
Ikram, M. K., De Jong, F. J., Van Dijk, E. J., Prins, N. D., Hofman, A., Breteler, M. M. 
B., & De Jong, P. (2006). Retinal vessel diameters and cerebral small vessel 
disease: the Rotterdam Scan Study. Brain, 129, 182-188. 
doi:10.1093/brain/awh688 
 
Ikram, M. K., de Jong, F. J., Vingerling, J. R., Witteman, J. C. M., Hofman, A., Breteler, 
M. M. B., & de Jong, P. (2004). Are retinal arteriolar or venular diameters 
associated with markers for cardiovascular disorders? The Rotterdam Study. 
Investigative Ophthalmology & Visual Science, 45(7), 2129-2134. 
doi:10.1167/iovs.03-1390 
 
Ikram, M. K., Ong, Y. T., Cheung, C. Y., & Wong, T. Y. (2013). Retinal Vascular 
Caliber Measurements: Clinical Significance, Current Knowledge and Future 
Perspectives. Ophthalmologica, 229(3), 125-136. doi:10.1159/000342158 
 
Jacobus, J., Goldenberg, D., Wierenga, C. E., Tolentino, N. J., Liu, T. T., & Tapert, S. F. 
(2012). Altered cerebral blood flow and neurocognitive correlates in adolescent 
cannabis users. Psychopharmacology, 222(4), 675-684. doi:10.1007/s00213-012-
2674-4 
 
Johns, L. C., Cannon, M., Singleton, N., Murray, R. M., Farrell, M., Brugha, T., . . . 
Meltzer, H. (2004). Prevalence and correlates of self-reported psychotic 
symptoms in the British population. British Journal of Psychiatry, 185, 298-305. 
doi:10.1192/bjp.185.4.298 
 
Jones, R. T. (2002). Cardiovascular system effects of marijuana. Journal of Clinical 
Pharmacology, 42(11), 58S-63S. doi:10.1177/0091270002238795 
 
Jouanjus, E., Lapeyre-Mestre, M., Micallef, J., & French Assoc Regional Abuse, D. 
(2014). Cannabis Use: Signal of Increasing Risk of Serious Cardiovascular 
Disorders. Journal of the American Heart Association, 3(2). 
doi:10.1161/jaha.113.000638 
 
Keel, S., Koklanis, C., Vukicevic, M., Itsiopoulos, C., & Brazionis, L. (2014). Diabetes, 
diabetic retinopathy, and retinal vascular alterations: a systematic review. The 
Asia-Pacific Journal of Ophthalmology, , 3(3), 164-171. doi: 
10.1097/APO.0000000000000053 
 
Kelleher, I., & Cannon, M. (2011). Psychotic-like experiences in the general population: 
characterizing a high-risk group for psychosis. Psychological Medicine, 41(1), 1-
6. doi:10.1017/s0033291710001005 
 
Kifley, A., Liew, G., Wang, J. J., Kaushik, S., Smith, W., Wong, T. Y., & Mitchell, P. 
(2007). Long-term effects of smoking on retinal microvascular caliber. American 
Journal of Epidemiology, 166(11), 1288-1297. doi:10.1093/aje/kwm255 
 29 
 
Kim, D. H., Newman, A. B., Hajjar, I., Strotmeyer, E. S., Klein, R., Newton, E., . . . 
Lipsitz, L. A. (2011). Retinal Microvascular Signs and Functional Loss in Older 
Persons The Cardiovascular Health Study. Stroke, 42(6), 1589-1595. 
doi:10.1161/strokeaha.110.605261 
 
Klag, M. J., Moore, R. D., Sakai, Y., Sasaki, S., Stone, R. W., & Comstock, G. W. 
(1989). Alcohol-use and retinal-vessels - insights into the mechanism of alcohol-
induced stroke. International Journal of Epidemiology, 18(3), 619-625. 
doi:10.1093/ije/18.3.619 
 
Klein, R., Klein, B. E. K., Knudtson, M. D., Wong, T. Y., & Tsai, M. Y. (2006). Are 
inflammatory factors related to retinal vessel caliber? The Beaver Dam Eye 
Study. Archives of Ophthalmology, 124(1), 87-94. doi:10.1001/archopht.124.1.87 
 
Kline, E., Wilson, C., Ereshefsky, S., Tsuji, T., Schiffman, J., Pitts, S., & Reeves, G. 
(2012). Convergent and discriminant validity of attenuated psychosis screening 
tools. Schizophrenia Research, 134(1), 49-53. doi:10.1016/j.schres.2011.10.001 
 
Knudtson, M. D., Lee, K. E., Hubbard, L. D., Wong, T. Y., Klein, R., & Klein, B. E. K. 
(2003). Revised formulas for summarizing retinal vessel diameters. Current Eye 
Research, 27(3), 143-149. doi:10.1076/ceyr.27.3.143.16049 
 
Leung, H., Wang, J. J., Rochtchina, E., Tan, A. G., Wong, T. Y., Hubbard, L. D., . . . 
Mitchell, P. (2003). Computer-assisted retinal vessel measurement in an older 
population: correlation between right and left eyes. Clinical and Experimental 
Ophthalmology, 31(4), 326-330. doi:10.1046/j.1442-9071.2003.00661.x 
 
Lien, Y. J., Huang, S. S., Liu, C. M., Hwu, H. G., Faraone, S. V., Tsuang, M. T., & Chen, 
W. J. (2013). A Genome-wide Quantitative Linkage Scan of Niacin Skin Flush 
Response in Families With Schizophrenia. Schizophrenia Bulletin, 39(1), 68-76. 
doi:10.1093/schbul/sbr054 
 
Liu, J., Gao, B., Mirshahi, F., Sanyal, A. J., Khanolkar, A. D., Makriyannis, A., & Kunos, 
G. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial 
cells. Biochemical Journal, 346, 835-840. doi:10.1042/0264-6021:3460835 
 
Lorenzi, M., Feke, G. T., Pitler, L., Berisha, F., Kolodjaschna, J., & McMeel, J. W. 
(2010). Defective Myogenic Response to Posture Change in Retinal Vessels of 
Well-Controlled Type 1 Diabetic Patients with No Retinopathy. Investigative 
Ophthalmology & Visual Science, 51(12), 6770-6775. doi:10.1167/iovs.10-5785 
 
Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states - 
comparison of the depression anxiety stress scales (dass) with the beck depression 
 30 
and anxiety inventories. Behaviour Research and Therapy, 33(3), 335-343. 
doi:10.1016/0005-7967(94)00075-u 
 
Lundqvist, T., Jonsson, S., & Warkentin, S. (2001). Frontal lobe dysfunction in long-term 
cannabis users. Neurotoxicology and Teratology, 23(5), 437-443. 
doi:10.1016/s0892-0362(01)00165-9 
 
Malaspina, D. (2013). Looking Schizophrenia in the Eye. American Journal of 
Psychiatry, 170(12), 1382-1384. doi:10.1176/appi.ajp.2013.13081136 
 
Malone, D. T., Hill, M. N., & Rubino, T. (2010). Adolescent cannabis use and psychosis: 
epidemiology and neurodevelopmental models. British Journal of Pharmacology, 
160(3), 511-522. doi:10.1111/j.1476-5381.2010.00721.x 
 
Mathew, R. J., Wilson, W. H., Chiu, N. Y., Turkington, T. G., Degrado, T. R., & 
Coleman, R. E. (1999). Regional cerebral blood flow and depersonalization after 
tetrahydrocannabinol administration. Acta Psychiatrica Scandinavica, 100(1), 67-
75. doi:10.1111/j.1600-0447.1999.tb10916.x 
 
Mathew, R. J., Wilson, W. H., Coleman, R. E., Turkington, T. G., & DeGrado, T. R. 
(1997). Marijuana intoxication and brain activation in marijuana smokers. Life 
Sciences, 60(23), 2075-2089. doi:10.1016/s0024-3205(97)00195-1 
 
Mathew, R. J., Wilson, W. H., Humphreys, D., Lowe, J. V., & Weithe, K. E. (1993). 
Depersonalization after marijuana smoking. Biological Psychiatry, 33(6), 431-
441. doi:10.1016/0006-3223(93)90171-9 
 
Mathew, R. J., Wilson, W. H., & Tant, S. R. (1989). Acute changes in cerebral blood-
flow associated with marijuana smoking. Acta Psychiatrica Scandinavica, 79(2), 
118-128. doi:10.1111/j.1600-0447.1989.tb08579.x 
 
McCreadie, R. G. (2003). Diet, smoking and cardiovascular risk in people with 
schizophrenia - Descriptive study. British Journal of Psychiatry, 183, 534-539. 
doi:10.1192/bjp.183.6.534 
 
McGeechan, K., Liew, G., Macaskill, P., Irwig, L., Klein, R., Klein, B. E. K., . . . Wong, 
T. Y. (2009). Prediction of Incident Stroke Events Based on Retinal Vessel 
Caliber: A Systematic Review and Individual-Participant Meta-Analysis. 
American Journal of Epidemiology, 170(11), 1323-1332. doi:10.1093/aje/kwp306 
 
Meier, M., Gillespie, N., Hansell, N., Hewitt, A., Hickie, I., Luc, Y., . . . Mackey, D. 
(2015). Retinal microvessels reflect familial vulnerability to psychotic symptoms: 
A comparison of twins discordant for psychotic symptoms and controls. 
Schizophrenia Research. http://dx.doi.org/10.1016/j.schres.2015.01.045 
 
 31 
Meier, M. H., Gillespie, N. A., Hansell, N. K., Hewitt, A. W., Hickie, I. B., Lu, Y., . . . 
Mackey, D. A. (2014). Associations Between Depression and Anxiety Symptoms 
and Retinal Vessel Caliber in Adolescents and Young Adults. Psychosomatic 
Medicine, 76(9), 732-738. doi:10.1097/psy.0000000000000117 
 
Meier, M. H., Shalev, W., Moffitt, T. E., Kapur, S., Keefe, R. S. E., Wong, T. Y., . . . 
Poulton, R. (2013). Microvascular Abnormality in Schizophrenia as Shown by 
Retinal Imaging. American Journal of Psychiatry, 170(12), 1451-1459. 
doi:10.1176/appi.ajp.2013.13020234 
 
Miller, T. J., Cicchetti, D., Markovich, P. J., McGlashan, T. H., & Woods, S. W. (2004). 
The sips screen: A brief self-report screen to detect the schizophrenia prodrome. 
Schizophrenia Research, 70(1), 78.  
 
Mir, A., Obafemi, A., Young, A., & Kane, C. (2011). Myocardial Infarction Associated 
With Use of the Synthetic Cannabinoid K2. Pediatrics, 128(6), E1622-E1627. 
doi:10.1542/peds.2010-3823 
 
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W. P., & De Hert, M. 
(2013). Prevalence of Metabolic Syndrome and Metabolic Abnormalities in 
Schizophrenia and Related Disorders-A Systematic Review and Meta-Analysis. 
Schizophrenia Bulletin, 39(2), 306-318. doi:10.1093/schbul/sbr148 
 
Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B., & Muller, J. E. (2001). 
Triggering myocardial infarction by marijuana. Circulation, 103(23), 2805-2809. 
http://dx.doi.org/10.1161/01.CIR.103.23.2805 
 
Morgan, V. A., McGrath, J. J., Jablensky, A., Badcock, J. C., Waterreus, A., Bush, R., . . 
. Mackinnon, A. (2014). Psychosis prevalence and physical, metabolic and 
cognitive co-morbidity: data from the second Australian national survey of 
psychosis. Psychological Medicine, 44(10), 2163-2176. 
doi:10.1017/s0033291713002973 
 
Nguyen, T. T., Wang, J. J., Sharrett, A. R., Islam, F. A., Klein, R., Klein, B. E., … Wong, 
T. Y. (2008). Relationship of Retinal Vascular Caliber With Diabetes and 
Retinopathy The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes 
care, 31(3), 544-549. doi: 10.2337/dc07-1528 
 
Osborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007). 
Relative risk of cardiovascular and cancer mortality in people with severe mental 
illness from the United Kingdom's General Practice Research Database. Archives 
of General Psychiatry, 64(2), 242-249. doi:10.1001/archpsyc.64.2.242 
 
 32 
Osby, U., Correia, N., Brandt, L., Ekbom, A., & Sparen, P. (2000). Mortality and causes 
of death in schizophrenia in Stockholm County, Sweden. Schizophrenia Research, 
45(1-2), 21-28. doi:10.1016/s0920-9964(99)00191-7 
 
Patton, N., Aslam, T., MacGillivray, T., Pattie, A., Deary, I. J., & Dhillon, B. (2005). 
Retinal vascular image analysis as a potential screening tool for cerebrovascular 
disease: a rationale based on homology between cerebral and retinal 
microvasculatures. Journal of Anatomy, 206(4), 319-348. doi:10.1111/j.1469-
7580.2005.00395.x 
 
Phan, K., Mitchell, P., Liew, G., Plant, A. J., Wang, S. B., Au, C., … Gopinath, B. 
(2015). Association between Retinal Arteriolar and Venule Calibre with Prevalent 
Heart Failure: A Cross-Sectional Study. PloS one,10(12), e0144850. doi: 
10.1371/journal.pone.0144850 
 
Radloff, L. (1977). The CES-D Scale: A self-report depression scale for research in the 
general population. Applied Psychological Measurement, 1(3), 385-401. 
doi: 10.1177/014662167700100306 
 
Rajesh, M., Mukhopadhyay, P., Batkai, S., Hasko, G., Liaudet, L., Huffman, J. W., . . . 
Pacher, P. (2007). CB2-receptor stimulation attenuates TNF-alpha-induced human 
endothelial cell activation, transendothelial migration of monocytes, and 
monocyte-endothelial adhesion. American Journal of Physiology-Heart and 
Circulatory Physiology, 293(4), H2210-H2218. doi:10.1152/ajpheart.00688.2007 
 
Roberts, R. E. (1980). Reliability of the ces-d scale in different ethnic contexts. 
Psychiatry Research, 2(2), 125-134. doi:10.1016/0165-1781(80)90069-4 
 
Rogers, S. L., Tikellis, G., Cheung, N., Tapp, R., Shaw, J., Zimmet, P. Z., . . . Wong, 
T.Y. (2008). Retinal arteriolar caliber predicts incident retinopathy. Diabetes 
Care, 31(4), 761-763. doi:10.2337/dc07-1622 
 
Ryan, M. C. M., Collins, P., & Thakore, J. H. (2003). Impaired fasting glucose tolerance 
in first-episode, drug-naive patients with schizophrenia. American Journal of 
Psychiatry, 160(2), 284-289. doi:10.1176/appi.ajp.160.2.284 
 
Schmidt-Kastner, R., van Os, J., Esquivel, G., Steinbusch, H. W. M., & Rutten, B. P. F. 
(2012). An environmental analysis of genes associated with schizophrenia: 
hypoxia and vascular factors as interacting elements in the neurodevelopmental 
model. Molecular Psychiatry, 17(12), 1194-1205. doi:10.1038/mp.2011.183 
 
Shean, G., & Baldwin, G. (2008). Sensitivity and specificity of depression questionnaires 
in a college-age sample. Journal of Genetic Psychology, 169(3), 281-288. 
doi:10.3200/gntp.169.3.281-292 
 
 33 
Sidney, S. (2002). Cardiovascular consequences of marijuana use. Journal of Clinical 
Pharmacology, 42(11), 64S-70S. doi:10.1177/0091270002238796 
 
Spelman, L. M., Walsh, P. I., Sharifi, N., Collins, P., & Thakore, J. H. (2007). Impaired 
glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic 
Medicine, 24(5), 481-485. doi:10.1111/j.1464-5491.2007.02092.x 
 
Stanley, C., & O'Sullivan, S. E. (2014). Vascular targets for cannabinoids: animal and 
human studies. British Journal of Pharmacology, 171(6), 1361-1378. 
doi:10.1111/bph.12560 
 
Stefanis, N. C., Delespaul, P., Henquet, C., Bakoula, C., Stefanis, C. N., & Van Os, J. 
(2004). Early adolescent cannabis exposure and positive and negative dimensions 
of psychosis. Addiction, 99(10), 1333-1341. doi:10.1111/j.1360-
0443.2004.00806.x 
 
Sugiura, T., Kodaka, T., Nakane, S., Kishimoto, S., Kondo, S., & Waku, K. (1998). 
Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, 
and cannabinoid CB1 receptor mRNA in human vascular cells: Is 2-
arachidonoylglycerol a possible vasomodulator? Biochemical and Biophysical 
Research Communications, 243(3), 838-843. doi:10.1006/bbrc.1998.8187 
 
Sun, C., Wang, J. J., Mackey, D. A., & Wong, T. Y. (2009). Retinal Vascular Caliber: 
Systemic, Environmental, and Genetic Associations. Survey of Ophthalmology, 
54(1), 74-95. doi:10.1016/j.survophthal.2008.10.003 
 
Thomas, G., Kloner, R. A., & Rezkalla, S. (2014). Adverse Cardiovascular, 
Cerebrovascular, and Peripheral Vascular Effects of Marijuana Inhalation: What 
Cardiologists Need to Know. American Journal of Cardiology, 113(1), 187-190. 
doi:10.1016/j.amjcard.2013.09.042 
 
Tunving, K., Thulin, S. O., Risberg, J., & Warkentin, S. (1986). Regional cerebral blood-
flow in long-term heavy cannabis use. Psychiatry Research, 17(1), 15-21. 
doi:10.1016/0165-1781(86)90037-5 
 
van Os, J., Bak, M., Hanssen, M., Bijl, R. V., de Graaf, R., & Verdoux, H. (2002). 
Cannabis use and psychosis: A longitudinal population-based study. American 
Journal of Epidemiology, 156(4), 319-327. doi:10.1093/aje/kwf043 
 
van Winkel, R., & Kuepper, R. (2014). Epidemiological, Neurobiological, and Genetic 
Clues to the Mechanisms Linking Cannabis Use to Risk for Nonaffective 
Psychosis. Annual Review of Clinical Psychology, Vol 10, 10, 767-791. 
doi:10.1146/annurev-clinpsy-032813-153631 
 
 34 
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse Health 
Effects of Marijuana Use. New England Journal of Medicine, 370(23), 2219-
2227. doi:10.1056/NEJMra1402309 
 
Volkow, N. D., Gillespie, H., Mullani, N., Tancredi, L., Grant, C., Valentine, A., & 
Hollister, L. (1996). Brain glucose metabolism in chronic marijuana users at 
baseline and during marijuana intoxication. Psychiatry Research-Neuroimaging, 
67(1), 29-38. doi:10.1016/0925-4927(96)02817-x 
 
Wang, X., Derakhshandeh, R., Liu, J., Narayan, S., Nabavizadeh, P., Le, S., ... & Sievers, 
R. E. (2016). One minute of marijuana secondhand smoke exposure substantially 
impairs vascular endothelial function. Journal of the American Heart 
Association, 5(8), e003858. 
 
Ward, P. E., Sutherland, J., Glen, E. M. T., & Glen, A. I. M. (1998). Niacin skin flush in 
schizophrenia: a preliminary report. Schizophrenia Research, 29(3), 269-274. 
doi:10.1016/s0920-9964(97)00100-x 
 
Wechsler, H., & McFadden, M. (1979). Drinking among college-students in new-england 
- extent, social correlates and consequences of alcohol-use. Journal of Studies on 
Alcohol, 40(11), 969-996. http://dx.doi.org/10.15288/jsa.1979.40.969 
 
Weiser, M., Knobler, H. Y., Noy, S., & Kaplan, Z. (2002). Clinical characteristics of 
adolescents later hospitalized for schizophrenia. American Journal of Medical 
Genetics, 114(8), 949-955. doi:10.1002/ajmg.10647 
 
Wolff, V., Armspach, J. P., Beaujeux, R., Manisor, M., Rouyer, O., Lauer, V., . . . Geny, 
B. (2014). High Frequency of Intracranial Arterial Stenosis and Cannabis Use in 
Ischaemic Stroke in the Young. Cerebrovascular Diseases, 37(6), 438-443. 
doi:10.1159/000363618 
 
Wong, T. Y., Islam, F. M. A., Klein, R., Klein, B. E. K., Cotch, M. F., Castro, C., . . . 
Shahar, E. (2006). Retinal vascular caliber, cardiovascular risk factors, and 
inflammation: The Multi-Ethnic Study of Atherosclerosis (MESA). Investigative 
Ophthalmology & Visual Science, 47(6), 2341-2350. doi:10.1167/iovs.05-1539 
 
Yau, J. W. Y., Xie, J., Lamoureux, E., Klein, R., Klein, B. E., Cotch, M. F., … Wong, T. 
Y. (2012). Retinal microvascular calibre and risk of incident diabetes: the multi-
ethnic study of atherosclerosis. Diabetes research and clinical practice, 95(2), 
265-274. doi: 10.1016/j.diabres.2011.10.027 
 
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002). Self reported 
cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: 
historical cohort study. British Medical Journal, 325(7374), 1199-1201. 
doi:10.1136/bmj.325.7374.1199 
  
3
5
 
 
Note. PLE+ indicates groups with psychotic-like experiences and PLE- indicates groups without psychotic-like experiences. CAN+ indicates cannabis user 
groups and CAN- indicates cannabis non-user groups. 
Note. Lifetime Cannabis Use is scored such that 0 = never used, 1 = used one or two times, 2 = used three to nine times, 3 = used 10 to 19 times, 4 = used 
20 to 39 times, 5 = used 40 to 99 times, 6 = used 100 to 199 times, 7 = used 200 to 500 times, and 8 = used more than 500 times. 
Note. For Lifetime Alcohol Use, participants indicated on how many days they had at least 1 alcoholic beverage, with 0 = never, 1 = 1 to 2 days, 2 = 3 to 9 
days, 3 = 10 to 19 days, 4 = 20 to 39 days, 5 = 40 to 99 days, and 6 = 100 days or more.
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Covariate
Arteriolar 
Diameter
Venular 
Diameter
PLE- vs. PLE+ CAN- vs. CAN+
r = -0.10 r = -0.004 φ = 0.03 φ= 0.25
p = .33 p = .97 p = .80 p = .013
r = 0.11 r = -0.10 φ = 0.06 φ = 0.15
p = .28 p = .30 p = .52 p = .14
r = -0.03 r = 0.05 φ = 0.22 φ = 0.37
p = .80 p = .64 p = .028 p < .001
r = 0.05 r = -0.09 r = 0.22 r = 0.68
p = .63 p = .36 p = .024 p <.001
r = -0.23 r = -0.08 φ = -0.12 φ = 0.01
p = .024 p = .43 p = .23 p = .92
r = -0.32 r = -0.05 r = 0.11 r = -0.09
p < .001 p = .62 p = .29 p = .38
r = -0.03 r = -0.02 r = 0.46 r = 0.13
p = .75 p = .85 p <.001 p = .18
r = -0.03 r = -0.07 r = 0.34 r = 0.09
p = .74 p = .47 p <.001 p = .37
Smoker
Note. Significant correlations at alpha <.05 level are in bold.
Note. Phi coefficients are reported for associations between dichotomous variables.
Depression
Anxiety
Lifetime Alcohol Use
High blood pressure
BMI
Table 2. Associations of covariates with each independent and dependent variable.
Sex
Race (White vs. Non-white)
Note. Male sex, white race, high blood pressure, smoker status, PLE+, and CAN+ are coded as 1.
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Figure 1. Mean venular diameter by PLE group. 
  
Note. Error bars indicate standard errors. 
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Figure 2. Mean venular diameter by cannabis group. 
  
Note. Error bars indicate standard errors. 
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Figure 3. Mean arteriolar diameter by PLE group 
  
Note. Error bars indicate standard errors. 
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Figure 4. Mean arteriolar diameter by cannabis group. 
  
Note. The standardized mean difference between the groups is 0.47, which is a medium effect size. Error bars indicate standard errors. 
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Figure 5. Mean arteriolar diameter by cannabis group, with and without adjustment for covariates.  
 
Note. All group differences remained significant when controlling for covariates. Error bars indicate standard errors. 
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APPENDIX A 
SUPPLEMENTAL ANALYSES 
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Supplement 1 
 To recruit cannabis users and non-users for this study, participants were originally 
screened for cannabis use based on the following criteria: individuals who had used 
cannabis 40 or more times during their lives and had used cannabis in the past month 
were recruited as users, and individuals who had used cannabis 20 or fewer times and had 
not used in the past month were recruited as non-users. Thus, for the primary analyses, I 
categorized participants who had used cannabis 40 or more times as users and those who 
had used 20 or fewer times as non-users.  
 However, there is currently no gold standard for classifying cannabis users versus 
non-users, and cut-offs on frequency of use to define users in the cannabis literature are 
variable. Because some participants in the current sample reported intermediate levels of 
cannabis use despite screening that aimed to capture heavy users and non-users, I 
repeated the ANOVAs for each dependent variable using two additional methods for 
classifying cannabis use groups.  
 First, I dichotomized the variable indexing number of lifetime uses of cannabis. I 
classified participants as cannabis users if they had used cannabis 40 or more times based 
on recruitment procedures, and as non-users if they had used fewer than 40 times. Using 
these cut-offs, all 107 participants with gradable retinal images from the original sample 
were included in analyses. I then tested associations of PLEs, cannabis use, and their 
interaction with venular and arteriolar diameter in this full sample.  
 Results were unchanged after reclassifying cannabis users. Mean retinal venular and 
arteriolar calibers for groups with and without PLEs and groups with and without 
cannabis use are presented in Supplemental Table 2. There was no significant difference 
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in venular diameter between groups with and without PLEs (F(1, 103)=0.00, p=.97). 
Likewise, there was no significant difference in venular diameter between cannabis users 
and non-users (F(1, 103)=0.34, p=.56). There was also no significant effect of an 
interaction between PLEs and cannabis use in predicting venular diameter (F(1, 
103)=0.30, p=.58).  
 For arteriolar diameter, there was no significant difference between groups with 
versus without psychotic-like experiences (F(1, 103)=0.02, p=.90). However, cannabis 
users had significantly greater mean arteriolar diameter than did non-users (F(1, 
103)=6.27, p=.014). There was no significant interaction between PLEs and cannabis use 
in predicting arteriolar diameter (F(1, 103)=1.00, p=.32).  
 Second, I created cannabis use groups that captured the extreme ends of the 
distribution of the lifetime frequency of cannabis use variable. I classified participants as 
cannabis users if they had used cannabis 200 or more times and as non-users if they had 
used fewer than 10 times, which resulted in a sample size of 84 participants. I then tested 
associations of PLEs, cannabis use, and their interaction with venular and arteriolar 
diameter in this sub-sample of participants.  
 Using this classification method, results remained unchanged. Mean retinal venular 
and arteriolar calibers for each group are presented in Supplemental Table 3.  There was 
no significant difference in venular diameter between groups with PLEs and groups 
without PLEs (F(1, 80)=0.26, p=.61), or for cannabis users versus non-users (F(1, 
80)=0.18, p=.67). There was also no significant interaction between PLEs and cannabis 
use in predicting venular diameter (F(1, 80)=0.31, p=.58).  
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 For arteriolar diameter, there was no significant difference between groups with 
versus without psychotic-like experiences (F(1, 80)=0.00, p=.96), although there was a 
difference between cannabis users and non-users such that users had significantly greater 
mean arteriolar diameter than did non-users (F(1, 80)=6.04, p=.016). The interaction 
between PLEs and cannabis use in predicting arteriolar diameter was not significant (F(1, 
80)=2.22, p=.14).  
Supplement 2 
 To test whether acute effects of cannabis use could account for the finding that 
cannabis users had greater mean arteriolar diameter than did non-users, I also conducted 
an ANCOVA with past 24-hour cannabis use included as a covariate. For this analysis, I 
used my original cannabis use classification method and tested for mean differences in 
arteriolar diameter between cannabis users and non-users, controlling for past 24-hour 
cannabis use. Results were unchanged: there was no statistically significant difference in 
arteriolar diameter between groups with and without psychotic-like experiences (F(1, 
96)=0.00, p=.98), cannabis users had significantly wider arterioles than did non-users 
(F(1, 96)=5.45, p=.022), and there was no statistically significant interaction between 
psychotic-like experiences and cannabis use (F(1, 96)=1.36, p=.25). Furthermore, past 
24-hour use was not a statistically significant predictor of arteriolar diameter (F(1, 
96)=0.37, p=.54). 
Supplement 3 
 Finally, to ensure that my results were not unduly influenced by potential outliers, I 
re-ran the original two-factor ANOVA predicting arteriolar diameter in two ways. First, I 
conducted the ANOVA with the observation approaching the cut-off of three standard 
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deviations above the mean excluded. Second, I conducted the ANOVA with this 
observation recoded to be equal to the nearest observed score.  
 Results remained unchanged using each method. With the observation excluded, 
there was no statistically significant difference in mean arteriolar diameter between 
groups with and without psychotic-like experiences (F(1, 96)=0.02, p=.88), cannabis 
users had significantly wider arterioles than did non-users (F(1, 96)=5.47, p=.021), and 
the interaction between psychotic-like experiences and cannabis use was not statistically 
significant (F(1, 96)=1.90, p=.17). With the extreme observation recoded, there was no 
statistically significant difference in mean arteriolar diameter between groups with and 
without psychotic-like experiences (F(1, 97)=0.00, p=.98), cannabis users had 
significantly wider arterioles than did non-users (F(1, 97)=5.94, p=.017), and the 
interaction between psychotic-like experiences and cannabis use was not statistically 
significant (F(1, 97)=1.55, p=.22). 
 In sum, analyses using various methods to classify participants as cannabis users and 
non-users produced results that were consistent with initial analyses. Moreover, these 
results could not be accounted for by acute effects of cannabis use or by undue influence 
from extreme observations. The main effect of cannabis use on arteriolar diameter was 
significant in all supplemental analyses, and all other effects remained non-significant. 
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Study Study Sample N
Mean Age or 
Age Range
Mean Arteriolar 
Diameter in µm (SD)
Mean Venular 
Diameter in µm (SD)
Current Study College Student Health and Behavior 101 19.37 156.29 (10.32) 217.56 (15.42)
Ikram et al. (2004) Rotterdam Study 5674 ≥55 146.9 (14.4) 222.0 (20.9)
Kim et al. (2011) Cardiovascular Health Study 1744 78 166 (19) 191 (18)
Meier et al. (2013)
Dunedin Multidisciplinary Health and 
Development Study 922 38 137.3 (10.9) 196.2 (14.8)
Meier et al. (2014)
Brisbane Longitudinal Twins Study / 
Twins Eye Study of Tasmania 865 19.07 165.3 (12.9) 249.5 (18.0)
Meier et al. (2015)
Brisbane Longitudinal Twins Study / 
Twins Eye Study of Tasmania 531 20.6 163.88 (12.5) 249.7 (17.2)
Wong et al. (2006) Multi-Ethnic Study of Atherosclerosis 5979 45-84 144.1 (14.4) 214.0 (22.2)
Supplemental Table 1. Means and standard deviations for arteriolar and venular diameter in population-based samples.
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Supplemental Table 2. 
Groups with PLEs Groups without PLEs Cannabis Users Cannabis Non-users
N=68 N=39 N=42 N=65
Mean Venular Diameter 217.90 (SD=15.08) 216.96 (SD=16.64) 218.41 (SD=14.31) 217.01 (SD=16.45)
Mean Arteriolar Diameter 156.78 (SD=11.07) 154.97 (SD=8.94) 159.10 (SD=9.94)* 154.19 (SD=10.20)*
*significant difference between group means
using 40+ times and non-users as individuals using < 40 times, results were unchanged.
Mean venular and arteriolar diameters by group. After re-defining cannabis users as individuals
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Supplemental Table 3.
Groups with PLEs Groups without PLEs Cannabis Users Cannabis Non-users
N=53 N=31 N=31 N=53
Mean Venular Diameter 218.15 (SD=15.70) 214.98 (SD=15.37) 217.91 (SD=15.56) 216.44 (SD=15.69)
Mean Arteriolar Diameter 157.05 (SD=11.27) 154.22 (SD=8.94) 159.28 (SD=10.75)* 154.09 (SD=9.96)*
*significant difference between group means
Mean venular and arteriolar diameters by group. After re-defining cannabis users as individuals
using 200+ times and non-users as individuals using < 10 times, results were unchanged.
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APPROVAL:CONTINUATION 
Madeline Meier 
Psychology 
- 
Madeline.Meier@asu.edu 
Dear Madeline Meier: 
On 6/20/2016 the ASU IRB reviewed the following protocol: 
The IRB approved the protocol from 6/20/2016 to 7/15/2017 inclusive.  Three weeks before 
7/15/2017 you are to submit a completed Continuing Review application and required 
attachments to request continuing approval or closure.  
If continuing review approval is not granted before the expiration date of 7/15/2017 approval of 
this protocol expires on that date. When consent is appropriate, you must use final, watermarked 
versions available under the “Documents” tab in ERA-IRB. 
In conducting this protocol you are required to follow the requirements listed in the 
INVESTIGATOR MANUAL (HRP-103). 
Sincerely,  
IRB Administrator 
Type of Review: Continuing Review 
Title: College Student Health and Behavior Study 
Investigator: Madeline Meier 
IRB ID: STUDY00001231 
Category of review: (8)(c) Data analysis 
Funding: None 
Grant Title: None 
Grant ID: None 
Documents Reviewed:  
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cc:  
Makita White 
Connor Jones 
Melanie Hill 
Lucia Carbajal 
Madeline Meier 
Amanda Bruening 
 
 
 
 
